scholarly journals Quality of life score is primarily affected by the mental rather than the physical component in patients with restless legs syndrome

2009 ◽  
Vol 25 (1) ◽  
pp. 135-136 ◽  
Author(s):  
Christoforos D. Giannaki ◽  
Giorgos K. Sakkas ◽  
Georgios M. Hadjigeorgiou ◽  
Vassilios Liakopoulos ◽  
Georgios Anifandis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Restless Legs Syndrome ◽  
Life Score ◽  
Restless Legs

The Relationship between Restless Legs Syndrome and Quality of Life in Patients with Myasthenia Gravis

2019 ◽  
Vol 81 (3-4) ◽  
pp. 205-208
Author(s):  
Monica F. Ataide ◽  
Carolina da Cunha-Correia ◽  
Katia C.L. Petribú
Keyword(s):  
Quality Of Life ◽  
Myasthenia Gravis ◽  
Restless Legs Syndrome ◽  
Rating Scale ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Restless Legs ◽  
Study Population ◽  
Clinical Conditions

Background: Restless legs syndrome (RLS) is characterized for an uncomfortable sensation in legs and an irresistible desire to move them. This disorder has been more recently recognized in patients with myasthenia gravis (MG) and can interfere with the quality of life (QOL). Objectives: The aims of this study are to describe the prevalence of RLS and its severity and influence on the QOL in patients with MG. Method: This was a cross-sectional study conducted from May to June 2016 in Recife, Brazil. A sample of 42 patients was interviewed using a sociodemographic questionnaire, MG QOL questionnaire-15 and The RLS Rating Scale. Results: RLS was present in 47.6% of patients and of these 40.5% met moderate to severe RLS criteria. Patients were 45 years on average (SD ± 14.4) and women represented 57.1% of the study population. Among patients with RSL, the quality-of-life scores were worse (p = 0.010) on average. There was no association of RLS with the duration of MG, use of immunosuppressant or clinical conditions that could mimic the occurrence of RLS. Conclusion: RLS is a prevalent condition in patients with MG, and may be severe enough to negatively impact QOL.

P0019 Effect of pramipexole on quality of life in restless legs syndrome: results spanning 9 months

2007 ◽  
Vol 8 ◽  
pp. S74
Author(s):  
C. Trenkwalder ◽  
K. Stiasny-Kolster ◽  
A. Kupsch ◽  
W. Oertel ◽  
J. Koester
Keyword(s):  
Quality Of Life ◽  
Restless Legs Syndrome ◽  
Restless Legs

scholarly journals Time evolution of restless legs syndrome in haemodialysis patients

2019 ◽  
Author(s):  
Irene Capelli ◽  
Fabio Pizza ◽  
Marco Ruggeri ◽  
Lorenzo Gasperoni ◽  
Elisa Carretta ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kidney Transplantation ◽  
Restless Legs Syndrome ◽  
Statistical Significance ◽  
Dialysis Patients ◽  
Restless Legs ◽  
Continuous Form ◽  
Over Time

Abstract Background Restless legs syndrome (RLS) is characterized by an urge to move the extremities, accompanied by paraesthesiae, in the evening and at night. Uraemic RLS, a type of secondary RLS, occurs commonly in chronic kidney disease and end-stage renal disease. Progression of uraemic RLS over time is unclear. Therefore we investigated the prevalence, progression over time, risk factors and impact on survival of uraemic RLS in a cohort of dialysis patients. Methods We reviewed at the 7-year follow-up a cohort of haemodialysis (HD) patients we had previously investigated for RLS, through interviews, validated questionnaires and analysis of demographic and clinical data. Results At the 7-year follow-up, RLS was present in 16% of patients, with a persistence rate of 33%. A correlation was obtained between RLS and older age, diabetes, low albumin and low body mass index. RLS was associated with reduced overall survival (median survival of 3.3 versus 3.7 years), particularly with the continuous form of RLS (1.61 years). There was a higher incidence of myocardial infarction and peripheral vascular disease, although not reaching statistical significance. RLS patients had absolute higher scores in all quality of life domains. A large majority of study patients (96%) reported being symptom-free within a few days or weeks following kidney transplantation. Conclusions The development of RLS, especially the continuous form, in patients undergoing HD has important consequences associated with decreased survival. Our results indicated an association between uraemic RLS and ageing, diabetes and malnutrition. Considerable efforts should be focused on the treatment of RLS, since it significantly and persistently impacts the quality of life of HD patients. Kidney transplantation could represent an effective treatment option for that RLS impacts on dialysis patients' quality of life, thus confirming the secondary nature of RLS in most HD patients.

scholarly journals The prevalence of common sleep disorders in young adults: a descriptive population-based study

SLEEP ◽  
2020 ◽  
Vol 43 (10) ◽  
Author(s):  
Nigel McArdle ◽  
Sarah V Ward ◽  
Romola S Bucks ◽  
Kathleen Maddison ◽  
Anne Smith ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Young Adults ◽  
Sleep Disorders ◽  
Sleep Disorder ◽  
Restless Legs Syndrome ◽  
Survey Methods ◽  
Apnea Hypopnea Index ◽  
Restless Legs ◽  
Obstructive Sleep

Abstract Sleep disorders in adults are associated with adverse health effects including reduced quality of life and increased mortality. However, there is little information on sleep disorders in young adults. A cross-sectional observational study was undertaken in 1,227 young adults participating in the Western Australian Pregnancy (Raine) Study (2012–2014) to describe the prevalence of common sleep disorders. In-laboratory polysomnography (PSG) and validated survey methods were used, including the Epworth Sleepiness Scale, Pittsburgh Sleep Symptom Questionnaire-Insomnia, and International Restless Legs Syndrome Study Group criteria. A total of 1,146 participants completed a core questionnaire, 1,051 completed a sleep-focused questionnaire and 935 had analyzable PSG data. Participants had a mean age of 22.2 years and female to male ratio of 1.1 to 1. The respective sleep disorder prevalences in females and males were: obstructive sleep apnea (OSA) (apnea-hypopnea index [AHI]: ≥5 events/hour) 14.9% (95% CI: 11.8–18.5) and 26.9% (95% CI: 22.9–31.2); chronic insomnia, 19.3% (95% CI: 16.7–23.9) and 10.6% (95% CI: 8.3–13.9); restless legs syndrome, 3.8% (95% CI: 2.4–5.6) and 1.9% (95% CI: 0.9–3.4); and abnormal periodic leg movements during sleep (>5 movements/hour), 8.6% (95% CI: 6.3–11.5) and 9.6% (95% CI: 7.1–12.7). There were statistically significant differences in prevalence between sexes for OSA and insomnia, which persisted after adjustment for body mass index and education. In those with complete data on all sleep-related assessments (n = 836), at least one sleep disorder was present in 41.0% of females and 42.3% of males. Sleep disorders are very common in young adults. Health practitioners should be aware of these high prevalences, as early identification and treatment can improve quality of life and may reduce later morbidity and mortality.

Neurology: Effect of Non-Ergot Dopamine Agonists on Health-Related Quality of Life of Patients with Restless Legs Syndrome

2009 ◽  
Vol 43 (5) ◽  
pp. 813-821 ◽  
Author(s):  
Ripple Talati ◽  
Olivia J Phung ◽  
Jeffrey Mather ◽  
Craig I Coleman
Keyword(s):  
Quality Of Life ◽  
Restless Legs Syndrome ◽  
Dopamine Agonists ◽  
Meta Analysis ◽  
Health Related Quality ◽  
Restless Legs ◽  
Hrqol Data ◽  
Related Quality ◽  
Health Related

Background Non-ergot dopamine agonists (NEDAs) have become the gold-standard agents for the treatment of restless legs syndrome (RLS). While the efficacy and safety of these drugs have been widely studied, their effect on patients' health-related quality of life (HRQoL) has not been fully elucidated. Objective To better define the usefulness of NEDAs by assessing their impact on HRQoL. Methods We performed a meta-analysis of randomized, double-blind, placebo-controlled trials evaluating the use of NEDAs in patients with RLS. A systematic literature search of MEDLINE, EMBASE, and Cochrane CENTRAL was performed from the earliest possible date through July 2008. Trials were included in the analysis if they evaluated NEDAs for the treatment of RLS and reported HRQoL using any RLS disease-specific HRQoL instrument. HRQoL data were pooled and evaluated using an inverse variance weighting approach as standardized mean differences (SMDs) and 95% confidence interval (CI). For trials reporting HRQoL data obtained using the Johns Hopkins RLS-QoL Questionnaire, adjusted mean difference data were pooled to calculate the weighted mean difference (WMD) and 95% CI. Results Seven trials (N = 1483) met all inclusion criteria. Patients with RLS taking NEDAs had significantly improved overall effect on HRQoL compared with those taking placebo (SMD 0.20; 95% CI 0.10 to 0.30; degree of inconsistency across studies [I2] = 0%). When analyzing trials using the Johns Hopkins RLS-QoL questionnaire, the results also showed improvement with NEDAs compared with placebo (WMD 4.72; 95% CI 2.96 to 6.47; I2 = 0%). Study conclusions were unchanged upon sensitivity analysis. The number of trials for each NEDA was small, limiting the usefulness of between-agent comparisons. Conclusions In patients with RLS, use of NEDAs showed improved HRQoL compared with placebo. Since pooled effect sizes observed in this meta-analysis appear to surpass accepted values for minimally important clinical differences, these improvements may be clinically relevant for the average studied patient. However, future studies evaluating long-term treatment of RLS with NEDAs are necessary, as are head-to-head comparative trials and economic assessments.

Sign in / Sign up

Export Citation Format

Share Document